vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 5.2

Indexed in: PubMed

CITESCORE 8.9

Neutralizing Antibodies after SARS-CoV-2 Vaccination

Guest Editors:

Prof. Dr. Tanja Vollmer
Heart and Diabetes Centre NRW, Institute for Laboratory and Transfusion Medicine, Ruhr-University Bochum, 32545 Bad Oeynhausen, Germany

Dr. Jonas Herzberg
Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, 21465 Reinbek, Germany

Dr. Bastian Fischer
Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum NRW, 32545 Bad Oeynhausen, Germany

Deadline for manuscript submissions:
closed (29 February 2024)

Message from the Guest Editors

Dear Colleagues,

COVID-19, caused by the SARS-CoV-2-virus, has placed a significant burden on healthcare systems and societies around the world. The approval of several vaccines has alleviated the global situation, forming a core element in the fight against the pandemic.

To further develop an ongoing vaccination protocol, including so-called booster vaccinations after primary immunization, reliable parameters are needed. The overall antibody response after infection or vaccination has been intensively studied. However, the role of neutralizing antibodies is still poorly understood, as their use is limited to highly specialized laboratories. The implementation of enzyme-linked immunosorbent assay (ELISA)-based surrogate virus neutralization tests (sVNTs), as well as cell-culture-based virus neutralization assays, could help us to gain a better understanding of these functional antibodies.

Therefore, this Special Issue "Neutralizing Antibodies after SARS-CoV-2 Vaccination" of *Vaccines* aims to focus on studies that report results of neutralizing antibodies after SARS-CoV-2 vaccination.

vaccines

IMPACT FACTOR 5.2 | Indexed in: PubMed | CITESCORE 8.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com